Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

  Agios Pharmaceuticals Inc ( AGIO ) |
2012 - 2021 (10 years)

Net Revenue (Sales) is 
$163.6M (1Y -4.94% )

AGIO Stock Price & Net Revenue (Sales)

Net Revenue (Sales) for AGIO competitors.
ALXN BMRN CELG EXEL GSK LLY PFE XNCR
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Revenue (Sales)

chevron_right 2021 $85.5M +3.5x
( +16.3% / year avg)
chevron_left 2012 $18.8M
vertical_align_top Peak $194.6M +9.35x
vertical_align_bottom Bottom $18.8M
arrow_drop_up # Up Years 7 7 of 10
years up.
arrow_drop_down # Down Years 3
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AGIO's stock price has drop +31.3% from $29.16 in 2012 , or -0.2x the rate relative to it's net revenue (sales) over the same period.
  • If AGIO grows it's stock at the same rate as it's net revenue (sales) (+16.3%/year) , it's stock price will grow +452% and hit $173.29 over the next 10 years.
  • AGIO's stock price has gone up 5 of the 7 years (+71%) it's net revenue (sales) were also up.
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
    1 Revenue 203196000 117912000 94387000 43011000 69892000 59119000 65358000 25548000 25106000
    2 Cost of Revenue 2805000.00 1317000.00 1397000.00 0.00 0.00 0.00 0.00 0.00 0.00
    3 Gross Profit (Income) 200391000.00 116595000.00 92990000.00 0.00 0.00 0.00 0.00 0.00 0.00
    4 R&D 367470000 410894000 341324000 292681000 220163000 141827000 100371000 54502000 41037000
    5 SG&A 149070000.00 132034000.00 114145000.00 71124000.00 50714000.00 35992000.00 19120000.00 9929000.00 7064000.00
    6 Other Expenses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    7 Operating Expenses 516540000 542928000 455469000 363805000 270877000 177819000 119491000 64431000 48101000
    8 Interest Expense 17832000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    9 D&A 9984000.00 8087000.00 7172000.00 6432000.00 5708000.00 3342000.00 1367000.00 1440000.00 1179000.00
    10 EBITDA -306165000 -418246000 -355307000 -314362000 -195277000 -115358000 -52766000 -37443000 -21816000
    11 Operating Income -316149000 -426333000 -362479000 -320794000 -200985000 -118700000 -54133000 -38883000 -22995000
    12 Other Income Expenses (Net) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    13 Pre-Income Tax -327370000 -411472000 -346028000 -314670000 -198471000 -117732000 -53930000 -38828000 -22926000
    14 Income Tax Expense 0.00 0.00 0.00 0.00 0.00 0.00 -426000.00 579000.00 -2824000.00
    15 Net Income -327370000 -411472000 -346028000 -314670000 -198471000 -117732000 -53504000 -39407000 -20102000
    16 EPS -5.46 -6.86 -6.03 -6.75 -5.07 -3.15 -1.59 -2.83 -1.18
    17 EPS Diluted -5.46 -6.86 -6.03 -6.75 -5.07 -3.15 -1.59 -2.83 -1.18
    18 Shares Outstanding 69271163 59994539 57418300 46587631 39126400 37429262 33667024 15415000 23133283
    19 Shares Outstanding (Diluted) 69271163 59994539 57418300 46587631 39126400 37429262 33667024 15415000 23133283
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
    1 Cash & Cash Equivalents 127436000 80931000 70502000 102724000 160754000 71764000 14031000 71560000 91297000
    2 Short Term Investments 445493000 483946000 514800000 321212000 380560000 245238000 328034000 95209000 36679000
    3 Cash & S-T Investments 572929000 564877000 585302000 423936000 541314000 317002000 342065000 166769000 127976000
    4 Accounts Receivables 25399000.00 15319000.00 10442000.00 3839000.00 8314000.00 11599000.00 12667000.00 476000.00 0.00
    5 Inventory 14698000.00 7331000.00 869000.00 0.00 0.00 0.00 0.00 0.00 0.00
    6 Other Current Assets 27722.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    7 Total Current Assets 636677000 611704000 613780000 445261000 559892000 337329000 359546000 169747000 130144000
    8 PP&E 117542000.00 31472000.00 24320000.00 24431000.00 25337000.00 23220000.00 6386000.00 3758000.00 3565000.00
    9 Goodwill 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    10 Intangible Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    11 Goodwill & Intangible Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    12 L-T Investments 445493.00 153000000.00 220000000.00 144000000.00 32000000.00 59000000.00 125000000.00 27000000.00 0.00
    13 Tax Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2706000.00
    14 Other Non-Current Assets 1125000.00 0.00 238000.00 891000.00 1615000.00 611000.00 590000.00 575000.00 593000.00
    15 Total Non-Current Assets 216275000.00 279037000.00 244677000.00 169136000.00 59202000.00 82736000.00 132358000.00 31458000.00 6864000.00
    16 Other Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    17 Total Assets 852952000 890741000 858457000 614397000 619094000 420065000 491904000 201205000 137008000
    18 Accounts Payables 26844000.00 21896000.00 17880000.00 22767000.00 17106000.00 14748000.00 11067000.00 3678000.00 3308000.00
    19 S-T Debt 97458.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    20 Income Tax Payables 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    21 Deferred Revenue 0.00 10933000.00 32710000.00 37842000.00 35913000.00 19665000.00 35686000.00 25072000.00 25072000.00
    22 Other Current Liabilities 0.00 0.00 0.00 0.00 0.00 0.00 6000.00 9000.00 65000.00
    23 Total Current Liabilities 94394000 92886000 93503000 94941000 88433000 52888000 61089000 36930000 35113000
    24 L-T Debt 163811.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
    1 Net Income (Earnings) -327370000 -411472000 -346028000 -314670000 -198471000 -117732000 -53504000 -39407000 -20102000
    2 D&A 9984000.00 8087000.00 7172000.00 6432000.00 5708000.00 3342000.00 1367000.00 1440000.00 1179000.00
    3 Deferred Income Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3842000.00 6707000.00
    4 Stock-Based Compensation (SBC) 75122000.00 72373000.00 73357000.00 47809000.00 42086000.00 31963000.00 11506000.00 3030000.00 742000.00
    5 Change in Working Capital 23465000.00 -1459000.00 169957000.00 -121139000.00 187018000.00 -14016000.00 165640000.00 37786000.00 -47396000.00
    6 Accounts Receivables -10060000.00 -4877000.00 -6772000.00 1216000.00 3339000.00 -1733000.00 -6016000.00 0.00 0.00
    7 Inventory -7367000.00 -6462000.00 -869000.00 0.00 0.00 0.00 0.00 0.00 0.00
    8 Accounts Payables 5889000.00 3716000.00 -5488000.00 5329000.00 3501000.00 4215000.00 7577000.00 30000.00 -322000.00
    9 Other Working Capital 542283000 518818000 520277000 350320000 471459000 284441000 298457000 132817000 95031000
    10 Other Non-Cash Items 19520000.00 8532000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    11 Net Cash Provided by Operating Activities -290759000 -370622000 -304421000 -285232000 38562000 -76949000 -59353000 -56400000 -49548000
    12 Investments in PP&E -14909000.00 -12171000.00 -6986000.00 -4627000.00 -9915000.00 -20164000.00 -2216000.00 -1294000.00 -1475000.00
    13 Acquisitions (Net) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    14 Purchase of Investments -557030000 -488566000 -933320000 -688702000 -506067000 -353177000 -837219000 -146049000 -88524000
    15 Sales/Maturities of Investments 647685000 592177000 666481000 635421000 396632000 501650000 505528000 60126000 113041000
    16 Other Investing Activities 0.00 0.00 0.00 0.00 0.00 0.00 571000.00 0.00 0.00
    17 Net Cash used for Investing Activities 75746000 91440000 -273825000 -57908000 -119350000 128309000 -333336000 -87217000 23042000
    18 Debt Repayment -336000.00 -113000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    19 Common Stock Issued 0.00 277201000.00 516206000.00 270250000.00 162150000.00 0.00 333577000.00 126117000.00 0.00
    20 Common Stock Repurchased 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    21 Dividends Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    22 Other Financing Activities 250537000.00 0.00 -391000.00 638000.00 -230000.00 -207000.00 -720000.00 -2387000.00 0.00
    23 Net Cash Used Provided by Financing Activities 261518000.00 289611000.00 546024000.00 285110000.00 169778000.00 6373000.00 335160000.00 123880000.00 142000.00
    24 Net Change in Cash 46505000 10429000 -32222000 -58030000 88990000 57733000 -57529000 -19737000 -26364000
  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 7/24/2013
    Stonk Exchange: NASDAQ
    • Agios Pharmaceuticals, Inc
    • is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases.
    • The company is headquartered in Cambridge, Massachusetts and currently employs 482 full-time employees.
    • The firm's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes.
    • The firm's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
    • These mutations are found in a range of hematological malignancies and solid tumors.
    • The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.
    • Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.